Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial
- Authors:
- DOI:
- 10.1093/annonc/mds335
- Abstract:
- Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC.
- Type:
- Journal article
- Language:
- Undetermined
- Published in:
- Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo, 2013, Vol 24, Issue 2, p. 309-14
- Keywords:
- Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Tumor Markers, Biological; Tumor Suppressor Proteins; Vinblastine; Young Adult
- Main Research Area:
- Medical science
- Publication Status:
- Published
- Review type:
- Peer Review
- Submission year:
- 2013
- Scientific Level:
- Scientific
- ID:
- 235260946
